Combined, these findings indicated that ZDQ-0620 has potential as a novel anti-cancer drug targeting the PI3K/AKT/mTOR pathway in CRC to inhibit tumor initiation and progression. This evidence concerns the gene AKT1 and colorectal carcinoma.